Evaluating and Monitoring Immune and Clinical Responses in Early-Stage Triple Negative Breast Cancer Undergoing Neoadjuvant Chemo-immunotherapy With Pembrolizumab
RecruitingOBSERVATIONAL
Enrollment
10
Participants
Timeline
Start Date
May 30, 2023
Primary Completion Date
April 10, 2026
Study Completion Date
April 10, 2027
Conditions
Breast Cancer Triple NegativeBreast Cancer Stage IIBreast Cancer Stage IIIBreast Cancer Invasive
Trial Locations (1)
30322
RECRUITING
Emory University/Winship Cancer Institute, Atlanta
All Listed Sponsors
collaborator
National Cancer Institute (NCI)
NIH
lead
Emory University
OTHER
NCT05877859 - Evaluating and Monitoring Immune and Clinical Responses in Early-Stage Triple Negative Breast Cancer Undergoing Neoadjuvant Chemo-immunotherapy With Pembrolizumab | Biotech Hunter | Biotech Hunter